NIAID Statement on AstraZeneca Vaccine
Late Monday, the Data and Safety Monitoring Board (DSMB) notified NIAID, BARDA, and AstraZeneca that it was concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial. The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data. We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible.
Authorization and guidelines for use of the vaccine in the United States will be determined by the Food and Drug Administration and Centers for Disease Control and Prevention after thorough review of the data by independent advisory committees.
Source: U.S. National Institutes of Health
- 271 reads
Human Rights
Fostering a More Humane World: The 28th Eurasian Economic Summi
Conscience, Hope, and Action: Keys to Global Peace and Sustainability
Ringing FOWPAL’s Peace Bell for the World:Nobel Peace Prize Laureates’ Visions and Actions
Protecting the World’s Cultural Diversity for a Sustainable Future
Puppet Show I International Friendship Day 2020